

# A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

NCT05610085

---

Status	RECRUITING
Phase	Phase 2
Sponsor	University of California, San Diego
Enrollment	133 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- at risk for seizures or suspected to be having seizures;
- all seizure aetiologies except correctable metabolic abnormalities such as hypoglycaemia and hypocalcaemia;
- Term neonates (corrected gestational age between 35 and 44 weeks, postnatal age less than 28 days);
- weight  $\geq$  2200g.
- Parental ability to comprehend and provide written informed consent

### Exclusion (4)

- Cumulative seizure burden of 8 minutes/ hour or more in phases 1 and 2, Cumulative seizure burden of 30 minutes/hour or more in phase 3;
- Renal failure defined as anuria in the first 24 hours of life;
- Subjects in whom death seems imminent;
- Seizures caused by correctable metabolic abnormality, such as hypocalcaemia, hypoglycaemia.

## Locations (5 total)

---

University of California, San Diego, San Diego, California, United States  
University of Minnesota, Minneapolis, Minnesota, United States  
Auckland City Hospital, Auckland, Auckland, New Zealand  
... and 2 more locations